Clinical Trials: A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma
Sponsor and CollaboratorsDana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Novartis
Contact
F. Stephen Hodi, MD
617-632-5053
Laurie Chiambalero, RN
617-632-5789
laurie_chiambalero@dfci.harvard.edu
Principal Investigator
F. Stephen Hodi, MD
Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier
NCT00788775
